Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

76 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Colon cancer (NSABP C-08 NCT00096278) - REGISTRATION FORM Colon cancer (NCT00096278)

- 20/09/2021 - 1 Formulaire, 3 Groupes Item, 64 Eléments de données, 1 Langue
Groupes Item: Header, Patient characteristics, Eligibility Checklist
NSABP PROTOCOL C-08: REGISTRATION FORM Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer NCT00096278 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D7F6865F-B506-428D-E034-0003BA12F5E7

Pre-Randomization Colon Cancer Stage III N0147 NCT00079274

- 20/09/2021 - 1 Formulaire, 12 Groupes Item, 70 Eléments de données, 1 Langue
Groupes Item: Header module, Visit, Protocol Administration, Patient Demographics/Pre-Treatment Characteristics, KRAS Results Contact, KRAS Results Contact (alternate), Eligibility Check, Contraindications, Pre-Randomization Check, The following will also be recorded:, The following will also be recorded:, Protocol Design
Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=70E10B08-8A7D-A35C-E040-BB89AD432A74

Kidney Cancer NCT01198158 Registration - CALGB 90802 Registration Worksheet Form - 3103555v1.0 - CALGB 90802 Registration Worksheet Form

- 20/09/2021 - 1 Formulaire, 10 Groupes Item, 44 Eléments de données, 1 Langue
Groupes Item: Header Module, Protocol Administration, Patient Demographics/Pre-Treatment Characteristics1, Patient Demographics/Pre-Treatment Characteristics2, Patient Demographics/Pre-Treatment Characteristics3, Certification Of Eligibility, Protocol Design, Initial Patient Consent For Specimen Use, CALGB 580902, Registration Information
CALGB 90802 Registration Worksheet Form Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=879626AD-DB8C-4AF2-E040-BB89AD4364E1

Metastatic Colorectal Cancer Fluorouracil Leucovorin Irinotecan Oxaliplatin NCT00077233 CALGB 80203 - HOSPITALIZATION FORM

- 14/07/2017 - 1 Formulaire, 1 Groupe Item, 14 Eléments de données, 1 Langue
Groupe Item: Header
Colorectal Cancer NCT00077233 Registration - CALGB: HOSPITALIZATION FORM - 2170963v3.0 CALGB: HOSPITALIZATION FORM Fluorouracil and Leucovorin Plus Either Irinotecan or Oxaliplatin With or Without Cetuximab in Treating Patients With Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum https://clinicaltrials.gov/ct2/show/NCT00077233

Colorectal Cancer NCT00265850 Registration - CALGB 80405 REGISTRATION WORKSHEET - 2672321v1.0 - CALGB 80405 REGISTRATION WORKSHEET

- 17/09/2021 - 1 Formulaire, 7 Groupes Item, 53 Eléments de données, 1 Langue
Groupes Item: Header Module, Protocol Administration, Patient Demographics/Pre-Treatment Characteristics1, Race, Certification Of Eligibility and Protocol Design, Companion Studies, Registration Information
A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab,or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patientswith Untreated Metastatic Adenocarcinoma of the Colon or Rectum Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=37A89102-B023-3CED-E044-0003BA3F9857

Kidney Cancer NCT01120249 Registration - Southwest Oncology Group S0931 Registration Worksheet Form (Form #62788) - 2992250v1.0 - Southwest Oncology Group S0931 Registration Worksheet Form (Form #62788)

- 09/01/2015 - 1 Formulaire, 9 Groupes Item, 23 Eléments de données, 1 Langue
Groupes Item: Protocol Information, SWOG PATIENT ID, DEMOGRAPHY, For SWOG Institutions:, Patient Information, Stratification Questions, Indicate how the patient answered the following questions on the consent form, Patient Eligibility, Auxiliary Question
Southwest Oncology Group S0931 Registration Worksheet Form (Form #62788) Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=7DFFD6EC-BC3B-4B34-E040-BB89AD4345BB

Kidney Cancer NCT01120249 Pre-Study - Southwest Oncology Group S0931 Prestudy Form (Form #6723) - 3000230v1.0 - Southwest Oncology Group S0931 Prestudy Form (Form #6723)

- 09/01/2015 - 1 Formulaire, 6 Groupes Item, 58 Eléments de données, 1 Langue
Groupes Item: Header Module, PATIENT AND DISEASE DESCRIPTION, Pathologic stage of disease, LABORATORY VALUES, LABORATORY VALUES1, Comments
Southwest Oncology Group S0931 Prestudy Form (Form #6723) Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=7E26DCC6-D288-5564-E040-BB89AD433E24

Liver Cancer NCT01015833 Registration - CALGB 80802 Registration Worksheet Form - 2940585v1.0 - CALGB 80802 Registration Worksheet Form

- 17/09/2021 - 1 Formulaire, 10 Groupes Item, 45 Eléments de données, 1 Langue
Groupes Item: Header Module, Protocol Administration, Patient Demographics/Pre-Treatment Characteristics1, Patient Demographics/Pre-Treatment Characteristics2, Patient Demographics/Pre-Treatment Characteristics3, Certification Of Eligibility, Protocol Design, Optional Companion Studies, Registration Information, Notes
CALGB 80802 Registration Worksheet Form Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=73B6D8AE-48AF-7324-E040-BB89AD43648A

Pancreatic Cancer NCT00733746 Registration - ACOSOG-Z5041 Registration Worksheet - 2921129v1.0 - ACOSOG-Z5041 Registration Worksheet

- 20/09/2021 - 1 Formulaire, 4 Groupes Item, 34 Eléments de données, 1 Langue
Groupes Item: Header Module, Eligibility Criteria, Diagnosis and Therapy, Specimen Banking Consent
ACOSOG-Z5041 Registration Worksheet Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6F3D4C5B-FB42-7755-E040-BB89AD432E97

Pancreatic Cancer NCT00733746 Registration - Z5041 - OPEN Enrollment Form - 3013792v1.0 - Z5041 - OPEN Enrollment Form

- 17/09/2021 - 1 Formulaire, 3 Groupes Item, 44 Eléments de données, 1 Langue
Groupes Item: Demography Section, General Information, Eligibility Checklist
Z5041 - OPEN Enrollment Form Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=7FFA1514-8347-A58F-E040-BB89AD4376E5

E2805 Second Primary Form NCT00326898

- 16/06/2015 - 1 Formulaire, 4 Groupes Item, 18 Eléments de données, 1 Langue
Groupes Item: Header, Patient demographics, Second primary cancer assessment, Footer module
E2805 Second Primary Form NCT00326898 Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=054BADA9-3263-36C2-E044-0003BA3F9857

Pancreatic Cancer NCT00075686 Pre-Study - S0205 Advanced GI Carcinoma Prestudy Form - 2035482v3.0 - S0205 Advanced GI Carcinoma Prestudy Form

- 09/01/2015 - 1 Formulaire, 5 Groupes Item, 19 Eléments de données, 1 Langue
Groupes Item: Header, DESCRIPTION OF DISEASE, PRIOR TREATMENT RELATED TO THIS CANCER, Comments, CCRR MODULE
S0205 Advanced GI Carcinoma Prestudy Form S0205 Gemcitabine With or Without Cetuximab as First-Line Therapy in Treating Patients With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A11A5640-9768-6C93-E034-080020C9C0E0

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial